Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, focuses on developing and marketing products to urologists, endocrinologists, orthopedists, and select primary care physicians primarily in the United States. It markets Testim, a topical 1% testosterone gel, for the treatment of hypogonadism. The company’s products in clinical development include AA4500, an injectable collagenase enzyme, which is in Phase III of development for the treatment of Dupuytren’s contracture, and in Phase II of development for the treatment of Peyronie’s Disease and Frozen Shoulder Syndrome. Auxilium, using its transmucosal film delivery system also develops AA4010, which is in Phase I of development for the treatment of overactive bladder. In addition, the company has two pain products using its transmucosal film delivery system in pre-clinical development. Further, it has rights to six additional pain products, and products for hormone replacement and urologic disease using its transmucosal film delivery system, and options to indications using AA4500 for non-topical formulations. The company was founded in 1999 and is headquartered in Malvern, Pennsylvania.